Antitumor activity of Zalypsis® (PM00104) in experimental models of bladder, gastric and liver cancer

被引：0
|
作者：
LePage, Doreen J. [1 ]
Sasak, Halina [1 ]
Guillen, Maria Jose [2 ]
Grant, Wendy [1 ]
Cuevas, Carmen [2 ]
Aviles, Pablo M. [2 ]
机构：
[1] PharmaMar USA Inc, Cambridge, MA USA
[2] PharmaMar, Madrid, Spain
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3546S / 3546S
页数：1
相关论文
共 50 条
  • [1] Evaluation of antitumor activity of PM00104 combined with Cisplatin in experimental models of bladder and gastric tumors
    Jose Guillen, Maria
    Lepage, Doreen
    Grant, Wendy
    Cuevas, Carmen
    Aviles, Pablo
    CANCER RESEARCH, 2009, 69
  • [2] Antitumor activity of PM00104 in hepatocellular carcinoma (HCC) experimental models
    Jose Guillen, Maria
    Lepage, Doreen
    Grant, Wendy
    Cuevas, Carmen
    Aviles, Pablo
    CANCER RESEARCH, 2009, 69
  • [3] Population pharmacokinetics of PM00104 (Zalypsis®) in cancer patients
    Carlos Pérez-Ruixo
    Belén Valenzuela
    Carlos Fernández Teruel
    Mario González-Sales
    Bernardo Miguel-Lillo
    Arturo Soto-Matos
    Juan José Pérez-Ruixo
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 15 - 24
  • [4] PM00104 (Zalypsis®): A Marine Derived Alkylating Agent
    Petek, Bradley J.
    Jones, Robin L.
    MOLECULES, 2014, 19 (08): : 12328 - 12335
  • [5] Antitumor effect of zalypsis (PM00104) in a human pancreatic adenocarcinoma orthotopic model
    Aviles, P.
    Cespedes, M. V.
    Soto-Montenegro, M. L.
    Guillen, M. J.
    Vaquero, J. J.
    Alamo, P.
    Cabrera, C.
    Mangues, R.
    Desco, M.
    Cuevas, C.
    EJC SUPPLEMENTS, 2010, 8 (07): : 88 - 88
  • [6] Population Pharmacokinetic–Pharmacodynamic Analysis of Neutropenia in Cancer Patients Receiving PM00104 (Zalypsis®)
    Mario González-Sales
    Belén Valenzuela
    Carlos Pérez-Ruixo
    Carlos Fernández Teruel
    Bernardo Miguel-Lillo
    Arturo Soto-Matos
    Juan Jose Pérez-Ruixo
    Clinical Pharmacokinetics, 2012, 51 : 751 - 764
  • [7] Population Pharmacokinetic-Pharmacodynamic Analysis of Neutropenia in Cancer Patients Receiving PM00104 (Zalypsis®)
    Gonzalez-Sales, Mario
    Valenzuela, Belen
    Perez-Ruixo, Carlos
    Fernandez Teruel, Carlos
    Miguel-Lillo, Bernardo
    Soto-Matos, Arturo
    Jose Perez-Ruixo, Juan
    CLINICAL PHARMACOKINETICS, 2012, 51 (11) : 751 - 764
  • [8] Profile of Zalypsis™ (PM00104) against various human solid tumors.
    Elices, M
    LePage, DJ
    Grant, WL
    Sasak, HT
    Caylor, T
    Guillen, MJ
    Martin, J
    Cuevas, C
    Aviles, P
    Faircloth, G
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9085S - 9086S
  • [9] Toxicokinetic evaluation of a novel anti-tumor agent, Zalypsis® (PM00104), in dogs
    Yin, Jainming
    Aviles, Pablo
    Wright, Teresa
    Guillen, Maria Jose
    Ly, Carl
    Lee, William
    Munt, Simon
    Cuevas, Carmen
    Faircloth, Glynn T.
    CANCER RESEARCH, 2006, 66 (08)
  • [10] Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors
    Ramón Salazar
    Antonio Calles
    Marta Gil
    Ignacio Durán
    Margarita García
    Manuel Hidalgo
    Cinthya Coronado
    Vicente Alfaro
    Mariano Siguero
    Carlos Fernández-Teruel
    Raquel Prados
    Emiliano Calvo
    Investigational New Drugs, 2014, 32 : 644 - 652
12345